London City Equities Limited

LCE

London City Equities Ltd. is a holding company, which engages in the provision of investment services. The company is headquartered in Sydney, New South Wales. The firm is focused on providing shareholders with attractive investment returns over the medium to longer terms by enhancing capital growth and pay dividends that over time grow faster than the rate of inflation. The principal activities of the Company consist of investment in Australian equities, predominantly those reflecting long term strategic advantage. From time to time the Company hold funds on deposit or with short term securities with trading banks. The firm is focused on investing in entities that have market shares and offer inherent growth. The company seeks to focus on its existing investments.

LCL Resources Limited

LCL

LCL Resources Ltd. engages in mineral exploration and mining. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-05-18. The firm is a gold/copper/nickel explorer with multiple assets in Papua New Guinea (PNG) and the mid-Cauca Gold Belt of Colombia. The Company’s segments include Mineral Exploration Colombia and Mineral Exploration Papua New Guinea. The company holds approximately 3890 square kilometers (Km2) of exploration titles in five regions of Papua New Guinea prospective for copper, gold, and nickel. The firm also holds position within the Quinchia region of the Mid-Cauca Gold Belt of Colombia. The firm is actively exploring in PNG while the 100% owned, 10,500 hectares (ha) Quinchia Gold Project in Colombia progresses through early-stage feasibility related studies. Its Quinchia Gold Project is located in central west Colombia, 100 kilometers (km) south of Medellin, in the department of Risaralda. Its Ono project consists of Kusi Target is prospective for high-grade gold skarn and copper/gold porphyry.

Laserbond Limited

LBL

Laserbond Ltd. engages in the reclamation and surface engineering of industrial components operating in severe environments and critical applications. The company is headquartered in Sydney, New South Wales and currently employs 141 full-time employees. The company went IPO on 2007-12-17. The firm is focused on the development and application of materials, technologies, and methodologies to increase operating performance and wear life of capital-intensive machinery components. The firm operates through three segments: Services, Products, Technology, and Research & Development. The Services segment includes the reclamation or repair of worn components for end users, or the manufacture of products that do not incorporate LaserBond cladding applications. The Products segment is engaged in the manufacture of products incorporating LaserBond cladding applications. The Technology segment is engaged in the sale of LaserBond cladding technology and associated licensing fees and consumables supply. The Research & Development segment includes ongoing development of new or improved technology, applications, and products. The company serves various industries, such as mining, drilling, mineral processing.

LBT Innovations Limited

LBT

LBT Innovations Ltd. engages in the business of researching, developing, and commercializing innovative technologies for healthcare and laboratory supply markets. The company is headquartered in Adelaide, South Australia and currently employs 17 full-time employees. The company went IPO on 2006-07-31. The firm is engaged in researching, developing and commercializing technologies for the healthcare and laboratory supply markets and manufacture and sales of the Automated Plate Assessment System (APAS Independence). Its products include APAS Independence, APAS Analysis Modules, APAS-AMR Analysis Module, and APAS PharmaQ. The APAS Independence is a platform technology that automates culture-plate screening and interpretation. The APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates. The APAS-AMR Analysis Module uses artificial intelligence mage analysis platform to read and interpret antimicrobial susceptibility tests (ASTs) for the detection of antimicrobial resistance (AMR). The APAS PharmaQC provides automated imaging, analysis and interpretation of microbiology culture plates used in environmental monitoring.